AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7884423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimens of IRS‐III
Number of subjects: 1062
Study 7884423 — intervention group
Group type: COMPARATOR
Intervention: Pulsed VAC or VAC-VADRC in IRS‐II
Number of subjects: 1062
Study 7884423 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex therapies evaluated in IRS‐III
Number of subjects: 1062
Study 2198311 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia at 42-43 degrees C before radiotherapy (33 patients)
Number of subjects: 65
Study 2198311 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (32 patients)
Number of subjects: 65
Study 353681 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet
Number of subjects: 46
Study 353681 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 46
Study 7181476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide (two-dose regimen)
Number of subjects: 150
Study 7181476 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin (six-dose regimen)
Number of subjects: 150
Study 30665464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA)
Number of subjects: 0
Study 30665464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30183338 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous moderate-intensity exercise (CMIE: 30 min, 50% peak power output)
Number of subjects: 8
Study 30183338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE: 5 × 4 min, 75% peak power output, work matched to CMIE)
Number of subjects: 8
Study 30183338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume sprint interval exercise (SIE: 4 × 30 s)
Number of subjects: 8
Study 30183338 — intervention group
Group type: COMPARATOR
Intervention: All protocols (CMIE, HIIE, SIE)
Number of subjects: 8
Study 26618796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile psychosocial intervention
Number of subjects: 25
Study 26618796 — intervention group
Group type: COMPARATOR
Intervention: Standard MMT
Number of subjects: 25
Study 24739445 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 224
Study 24739445 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 224
Study 23171536 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based guided self-help program (GSH-I)
Number of subjects: 175
Study 23171536 — intervention group
Group type: COMPARATOR
Intervention: cognitive-behavioral therapy (CBT)
Number of subjects: 175
Study 19903773 — intervention group
Group type: EXPERIMENTAL
Intervention: Classrooms cleaned daily with a quaternary ammonium wipe
Number of subjects: 6
Study 19903773 — intervention group
Group type: COMPARATOR
Intervention: Control classrooms (not cleaned daily)
Number of subjects: 6
Study 17712763 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 141
Study 17712763 — intervention group
Group type: COMPARATOR
Intervention: Self-administered therapy
Number of subjects: 141
Study 15774540 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective single embryo transfer
Number of subjects: 661
Study 15774540 — intervention group
Group type: COMPARATOR
Intervention: Double embryo transfer
Number of subjects: 661
Study 12198867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated elastomeric ligatures
Number of subjects: 14
Study 12198867 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fluoridated elastomeric ligatures
Number of subjects: 14
Study 12198867 — intervention group
Group type: COMPARATOR
Intervention: Control specimen (no elastomeric ligatures)
Number of subjects: 14
Study 9807603 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 16 ml/kg plus intravenous ephedrine boluses (0.1 mg/kg)
Number of subjects: 60
Study 9807603 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 8 ml/kg plus intramuscular depot ephedrine (0.5 mg/kg)
Number of subjects: 60
Study 9807603 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemaccel 8 ml/kg plus metaraminol infusion
Number of subjects: 60
Study 7695411 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery
Number of subjects: 44
Study 7695411 — intervention group
Group type: COMPARATOR
Intervention: Lateral thoracotomy
Number of subjects: 44
Study 7695411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 2566248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 40 mg
Number of subjects: 6
Study 2566248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 263938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate 5 mg/70 kg
Number of subjects: 12
Study 263938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate 10 mg/70 kg
Number of subjects: 12
Study 263938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate 15 mg/70 kg
Number of subjects: 12
Study 263938 — intervention group
Group type: COMPARATOR
Intervention: Dextroamphetamine sulfate 0 mg/70 kg (placebo)
Number of subjects: 12
Study 31004129 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH interventions
Number of subjects: 0
Study 31004129 — intervention group
Group type: EXPERIMENTAL
Intervention: IYCF interventions
Number of subjects: 0
Study 31703722 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS technology
Number of subjects: 0
Study 31703722 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced WBOTs
Number of subjects: 0
Study 31703722 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 28352657 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (EGFR inhibitor)
Number of subjects: 58
Study 28352657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (Src inhibitor)
Number of subjects: 58
Study 28352657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of erlotinib and dasatinib
Number of subjects: 58
Study 28352657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 26475403 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ng/mL cutoff
Number of subjects: 121
Study 26475403 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ng/mL cutoff
Number of subjects: 121
Study 26475403 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ng/mL cutoff
Number of subjects: 121
Study 25098502 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT-2-Quit (TXT) intervention
Number of subjects: 60
Study 25098502 — intervention group
Group type: COMPARATOR
Intervention: Daily non‐smoking related text messages (control condition)
Number of subjects: 60
Study 21330043 — intervention group
Group type: EXPERIMENTAL
Intervention: CBRN-PPE
Number of subjects: 48
Study 21330043 — intervention group
Group type: COMPARATOR
Intervention: Normal clothes
Number of subjects: 48
Study 18759847 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for estimating the complier average causal effect (CACE)
Number of subjects: 0
Study 18759847 — intervention group
Group type: COMPARATOR
Intervention: Assumed nonignorable missing-data model
Number of subjects: 0
Study 17602732 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 vaccine
Number of subjects: 9258
Study 17602732 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Control)
Number of subjects: 9258
Study 14991337 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A treatment
Number of subjects: 46
Study 14991337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 10971315 — intervention group
Group type: EXPERIMENTAL
Intervention: ORAL
Number of subjects: 7
Study 10971315 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 7
Study 10971315 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI + C
Number of subjects: 7
Study 10971315 — intervention group
Group type: COMPARATOR
Intervention: ORAL + C
Number of subjects: 7
Study 9338882 — intervention group
Group type: EXPERIMENTAL
Intervention: Multichannel surface electromyographic (EMG) signals during elbow flexion and extension
Number of subjects: 0
Study 9338882 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrogram representation of low-frequency EMG spectra
Number of subjects: 0
Study 9338882 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar representation of low-frequency spectra of multichannel EMG
Number of subjects: 0
Study 8408368 — intervention group
Group type: COMPARATOR
Intervention: Behavioural management plus relaxation placebo
Number of subjects: 27
Study 8408368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioural-cognitive self-management approach
Number of subjects: 27
Study 3775141 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program for treatment of hypertension (10 weeks duration)
Number of subjects: 21
Study 31675086 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening using the Patient Health Questionnaire‐9 (PHQ‐9) from September through December of the academic year.
Number of subjects: 9650
Study 31675086 — intervention group
Group type: COMPARATOR
Intervention: Targeted screening based on observable behavior (current process).
Number of subjects: 9650
Study 27523435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) or fluticasone propionate
Number of subjects: 2672
Study 27523435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2672
Study 24523054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration
Number of subjects: 16
Study 24523054 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 16
Study 22928579 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Number of subjects: 1562
Study 22928579 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting more than an hour to smoke after waking and intention to quit within 30 days at baseline
Number of subjects: 1562
Study 20818967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 0
Study 20818967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19104769 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (3 g/day, n = 28)
Number of subjects: 54
Study 19104769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 54
Study 17001068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m² administered on days 1, 4, 8, and 11 of a 21-day cycle, for up to 17 cycles.
Number of subjects: 155
Study 14557435 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily for 3 months, then 1000 mg twice daily for 3 months)
Number of subjects: 52
Study 14557435 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol (35 micro g)‐cyproterone acetate (2 mg) oral contraceptive pills
Number of subjects: 52
Study 10389531 — intervention group
Group type: EXPERIMENTAL
Intervention: Target pressure < or = 90 mmHg
Number of subjects: 18790
Study 10389531 — intervention group
Group type: EXPERIMENTAL
Intervention: Target pressure < or = 85 mmHg
Number of subjects: 18790
Study 10389531 — intervention group
Group type: EXPERIMENTAL
Intervention: Target pressure < or = 80 mmHg
Number of subjects: 18790
Study 10389531 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg aspirin 1 dd
Number of subjects: 18790
Study 8965185 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (Group 1, n = 10)
Number of subjects: 18
Study 8965185 — intervention group
Group type: COMPARATOR
Intervention: Placebo bolus infusions (Group 2, n = 8)
Number of subjects: 18
Study 1324462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG fermented milk product
Number of subjects: 39
Study 1324462 — intervention group
Group type: COMPARATOR
Intervention: Pasteurized yogurt (placebo group)
Number of subjects: 39
Study 6407812 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. verapamil, 5‐10 mg/h for two days
Number of subjects: 29
Study 6407812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 29
Study 31478125 — intervention group
Group type: EXPERIMENTAL
Intervention: High monocyte count (HMC) group (monocytes ≥ 0.53 × 10^9/L)
Number of subjects: 206
Study 31478125 — intervention group
Group type: COMPARATOR
Intervention: Low monocyte count (LMC) group (monocytes < 0.53 × 10^9/L)
Number of subjects: 206
Study 31277091 — intervention group
Group type: EXPERIMENTAL
Intervention: TrueCPR device
Number of subjects: 94
Study 28558697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aid provided
Number of subjects: 20
Study 28558697 — intervention group
Group type: COMPARATOR
Intervention: No cognitive aid
Number of subjects: 20
Study 26934986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 70
Study 26934986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24530146 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered microneedle patches
Number of subjects: 91
Study 24530146 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle patches (snap device)
Number of subjects: 91
Study 24530146 — intervention group
Group type: COMPARATOR
Intervention: Placebo microneedle patches
Number of subjects: 91
Study 22153707 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-5FU group
Number of subjects: 50
Study 22153707 — intervention group
Group type: COMPARATOR
Intervention: 5FU group
Number of subjects: 50
Study 20980359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux haemodialysis
Number of subjects: 18
Study 20980359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux haemodialysis
Number of subjects: 18
Study 20980359 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration
Number of subjects: 18
Study 20980359 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 18055489 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine eye drops
Number of subjects: 330
Study 18055489 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin eye drops
Number of subjects: 330
Study 18055489 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 330
Study 16229236 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 46
Study 16229236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12011795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (5000 lux from 6-8 a.m.) and imipramine 150 mg/day
Number of subjects: 34
Study 12011795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (5000 lux from 6-8 a.m.) and imipramine-like placebo
Number of subjects: 34
Study 12011795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim red light (500 lux from 6-8 a.m.) and imipramine 150 mg/day
Number of subjects: 34
Study 10470708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 14
Study 10470708 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide
Number of subjects: 14
Study 8547196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive surveillance including physician visits, bone scans, liver sonograms, chest X‐rays, and laboratory tests at predefined intervals (655 patients)
Number of subjects: 1320
Study 8547196 — intervention group
Group type: COMPARATOR
Intervention: Control regimen with clinically motivated tests (665 patients)
Number of subjects: 1320
Study 8547196 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measurements at 6, 12, 24 and 60 months
Number of subjects: 1320
Study 1298620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation (3 mMol/kg/day sodium chloride for 6 weeks)
Number of subjects: 66
Study 1298620 — intervention group
Group type: COMPARATOR
Intervention: Control (fed only on mothers' milk)
Number of subjects: 66
Study 6731757 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation anesthesia (ESA)
Number of subjects: 22
Study 6731757 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-enflurane anesthesia
Number of subjects: 22
Study 30121697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg for 1 week (n=10)
Number of subjects: 40
Study 30121697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 5 mg for 2 weeks followed by 2.5 mg for 6 weeks (n=14)
Number of subjects: 40
Study 29351658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure monitoring (frequent home blood pressure monitoring and 24-hour ambulatory blood pressure monitoring)
Number of subjects: 1048
Study 29351658 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood pressure monitoring (usual ad hoc blood pressure monitoring by office measurements)
Number of subjects: 1048
Study 29351658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure monitoring
Number of subjects: 1048
Study 29351658 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood pressure monitoring
Number of subjects: 1048
Study 25956933 — intervention group
Group type: EXPERIMENTAL
Intervention: New C-arm imaging platform
Number of subjects: 78
Study 23116881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 313
Study 23116881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 21767413 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized scanning rehabilitation program (Neuro Vision Technology (NVT) program) of 7 weeks at 3 times per week
Number of subjects: 0
Study 21767413 — intervention group
Group type: COMPARATOR
Intervention: Individualized therapy recommended by clinicians
Number of subjects: 0
Study 19339140 — intervention group
Group type: COMPARATOR
Intervention: Counseling Only
Number of subjects: 204
Study 19339140 — intervention group
Group type: COMPARATOR
Intervention: Counseling + Transfer
Number of subjects: 204
Study 19339140 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling + Methadone
Number of subjects: 204
Study 16780595 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mirror gonioscope (Goldmann)
Number of subjects: 99
Study 16780595 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mirror gonioscope (Sussman)
Number of subjects: 99
Study 16780595 — intervention group
Group type: COMPARATOR
Intervention: Auto-Keratometer
Number of subjects: 99
Study 16780595 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-based Sim K
Number of subjects: 99
Study 16780595 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both gonioscopes
Number of subjects: 99
Study 15267009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialyzers (8 different brands)
Number of subjects: 3
Study 11775412 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk subjects identified and treated during the study.
Number of subjects: 1200
Study 9467276 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prolactin concentrations
Number of subjects: 0
Study 1581948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine integrated with EPI
Number of subjects: 180
Study 1581948 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial groups (two different immunization schedules)
Number of subjects: 180
Study 1581948 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 4003628 — intervention group
Group type: EXPERIMENTAL
Intervention: Self report
Number of subjects: 0
Study 4003628 — intervention group
Group type: COMPARATOR
Intervention: Proxy report
Number of subjects: 0
Study 31738492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser with laser-assisted delivery of bimatoprost
Number of subjects: 40
Study 31738492 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser
Number of subjects: 40
Study 31738492 — intervention group
Group type: COMPARATOR
Intervention: Fractional ablative laser
Number of subjects: 40
Study 28701365 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie Method of Mechanical Diagnosis and Therapy (MDT)
Number of subjects: 148
Study 28701365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 24632743 — intervention group
Group type: EXPERIMENTAL
Intervention: Face cognition speed training
Number of subjects: 99
Study 20842406 — intervention group
Group type: EXPERIMENTAL
Intervention: Free base tablet formulation (180 mg)
Number of subjects: 12
Study 20842406 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphate salt capsule formulation (240 mg; 183 mg free base equivalent)
Number of subjects: 12
Study 20842406 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphate salt capsule formulation (200 mg) administered 3 times a week
Number of subjects: 12
Study 20836725 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-592379 (200 mg oral dose)
Number of subjects: 0
Study 20836725 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-592379
Number of subjects: 0
Study 17210880 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT participants (n = 953)
Number of subjects: 8469
Study 17210880 — intervention group
Group type: COMPARATOR
Intervention: Eligible nonenrolled patients (n = 4669)
Number of subjects: 8469
Study 17210880 — intervention group
Group type: COMPARATOR
Intervention: Ineligible patients (n = 2847)
Number of subjects: 8469
Study 16095449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/kg
Number of subjects: 60
Study 16095449 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 12390376 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy
Number of subjects: 55
Study 12390376 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy haemorrhoidectomy
Number of subjects: 55
Study 10089261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise program (cycling or walking, with optional stretching/light weights)
Number of subjects: 26
Study 10089261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise program
Number of subjects: 26
Study 7762464 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion detection in older subjects
Number of subjects: 36
Study 7762464 — intervention group
Group type: COMPARATOR
Intervention: Inversion detection in younger subjects
Number of subjects: 36